Physician-assisted doping of athletes has transformed high-performance sport into a chronically overmedicated subculture and spread so-called hormonal rejuvenation to the general public.
Marwan Hariz, MD, PhD and Jordan P. Amadio, MD, MBA
Deep brain stimulation (DBS) for enhancements of non-disease states is ethically indefensible given our incomplete knowledge of this technology. Attention should instead be focused on increasing access to DBS for patients with illnesses potentially treatable by the procedure.
In Association for Molecular Pathology v. Myriad Genetics, Inc., the Supreme Court ruled that synthetically created DNA is patentable, but the isolation of unaltered gene sequences is not.
AMA J Ethics. 2015;17(9):849-853. doi:
10.1001/journalofethics.2015.17.9.hlaw1-1509.
Concerns about the deleterious effects of stress on the mind and body have led to the beginnings of a stress vaccine, an injection that will reduce these effects.
David Elkin, MD, Erick Hung, MD, and Gilbert Villela, MD
The rapidly evolving field of neuroethics is concerned with the ethical questions that new technologies will pose about autonomy, privacy, the definition of normal, and individuality.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.
Publicizing physician ordering information as a way of peer-pressuring hospital employees into cutting costs is likely to have unintended consequences.
To prevent patients from avoiding care when they cannot afford it, providers should collaborate with them to eliminate unnecessary testing, reduce the frequency of follow-up visits where possible, and make manageable payment plans.
Believing that unnecessary use of resources is a significant contributor to rising health care costs, the ABIM Foundation launched the Choosing Wisely campaign, in which physicians and patients work together to develop treatment plans that are effective for the patient but are also efficient and promote the sustainable use of limited resources.
David S. Gierada, MD and Lawrence M. Kotner, Jr., MD
Despite strong supportive evidence on and professional society endorsement of CT screening for lung cancer, there is minimal demand from patients or physicians.